Close Menu

NEW YORK (GenomeWeb) – Foundation Medicine said today that it has signed a national agreement with UnitedHealthcare, under which the insurer will cover the firm's FoundationOne genomic profiling assay for patients with metastatic stage IV non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.